Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE
2024年7月19日 - 10:00PM
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), (“Shuttle
Pharma”), a discovery and development stage specialty
pharmaceutical company focused on improving outcomes for cancer
patients treated with radiation therapy (RT), today announced the
publication of a manuscript reporting on the ability of one of the
Company’s HDAC inhibitor pre-clinical assets, SP-1-303, which
exhibits ataxia-telangiectasia mutated protein (ATM) activation and
modulation of estrogen receptor expression resulting in substantial
growth inhibition of estrogen receptor positive breast cancer cells
(ER + BC).
The published manuscript, titled "Dual-targeting class I HDAC
inhibitor and ATM activator, SP-1-303, preferentially inhibits
estrogen receptor positive breast cancer cell growth,” reports the
work of Dr. Mira Jung, Professor of Radiation Medicine at
Georgetown University Medical Center, and Dr. Scott Grindrod,
Shuttle Pharma’s Principal Scientist, and was published in PLOS
ONE, a peer-reviewed open access journal published by the Public
Library of Science (PLOS).
SP-1-303, initially discovered and synthesized in Shuttle
Pharma’s laboratories by Dr. Grindrod, is one of the Company’s
pre-clinical selective Class I HDAC inhibitors. Histone deacetylase
inhibitors sensitize cancers to the effects of radiation, protect
normal tissues from radiation injury and activate the immune
system. SP-1-303 is a selective Class I HDAC inhibitor that
inhibits HDAC1, 3 and 6 and has direct cellular toxicity in ER +
BC. Furthermore, SP-1-303 increases the PD-L1 expression level in a
time-dependent manner, supporting combination of SP-1-303 with an
immune checkpoint blocker to enhance the therapeutic benefits.
“Inhibition of cancer cell growth with little effect on
surrounding normal cells is the desired strategy for treatment of
cancers,” commented Anatoly Dritschilo, M.D., CEO of Shuttle
Pharmaceuticals and a co-author of the report. “The report
highlights to the scientific and financial community how combined
targeting of Class I HDACs and ATM by SP-1-303 offers a promising
therapeutic approach for treating estrogen receptor positive breast
cancers and supports further preclinical evaluation as a potential
therapeutic agent.”
A copy of the publication is available at:
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0306168#sec018
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown University
Medical Center, Shuttle Pharma is a discovery and development stage
specialty pharmaceutical company focused on improving the outcomes
for cancer patients treated with radiation therapy (RT). Our
mission is to improve the lives of cancer patients by developing
therapies that are designed to maximize the effectiveness of RT
while limiting the side effects of radiation in cancer treatment.
Although RT is a proven modality for treating cancers, by
developing radiation sensitizers, we aim to increase cancer cure
rates, prolong patient survival and improve quality of life when
used as a primary treatment or in combination with surgery,
chemotherapy and immunotherapy. For more information, please visit
our website at www.shuttlepharma.com.
Safe Harbor Statement
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
“forward-looking statements.” These statements include, but are not
limited to, statements concerning the development of our company.
The words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “target,” “will,” “would” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including factors discussed in the “Risk
Factors” section of Shuttle Pharma’s Annual Report on Form 10-K for
the year ended December 31, 2023, filed with the SEC on March 20,
2024, as well other SEC filings. Any forward-looking statements
contained in this press release speak only as of the date hereof
and, except as required by federal securities laws, Shuttle
Pharmaceuticals specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Shuttle PharmaceuticalsAnatoly Dritschilo,
M.D., CEO240-403-4212 info@shuttlepharma.com
Investor ContactsLytham Partners, LLCRobert
Blum 602-889-9700shph@lythampartners.com
Shuttle Pharmaceuticals (NASDAQ:SHPH)
過去 株価チャート
から 6 2024 まで 7 2024
Shuttle Pharmaceuticals (NASDAQ:SHPH)
過去 株価チャート
から 7 2023 まで 7 2024